TerminatedPhase 2/3

Psoriatic Arthritis Study of Izokibep

Stopped: Per our 13Aug24 press release, we announced discontinuation of internal development in this indication. This decision was not due to safety reasons.

United States351 participantsStarted 2022-11-21

Plain-language summary

Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. nonsteroidal anti-inflammatory drug (NSAID)
✓. conventional-synthetic disease-modifying anti-rheumatic drugs (csDMARD) (i.e. methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, cyclosporine A)
✓. tumor necrosis factor-alpha inhibitor(s) (TNFi) (e.g. adalimumab, infliximab, etanercept, golimumab, certolizumab).

Exclusion criteria

✕. prolonged or recurrent diarrhea
✕. prolonged or recurrent abdominal pain
✕. blood in stool

What they're measuring

Number of Participants Who Achieved 50% Improvement in American College of Rheumatology (ACR50) at Week 16

Timeframe: Week 16

Trial details

NCT IDNCT05623345

SponsorACELYRIN Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-11-30

Results submitted2025-05-07

View on ClinicalTrials.gov More Psoriatic Arthritis trials